Biophytis Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Biophytis ont diminué à un taux annuel moyen de -4.9%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 7.7% par an.

Informations clés

-4.9%

Taux de croissance des bénéfices

52.3%

Taux de croissance du BPA

Biotechs Croissance de l'industrie	-14.6%
Taux de croissance des recettes	n/a
Rendement des fonds propres	n/a
Marge nette	n/a
Dernière mise à jour des bénéfices	31 Dec 2023

Mises à jour récentes des performances passées

Pas de mise à jour

Recent updates

Ventilation des recettes et des dépenses

Comment Biophytis gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

DB:6XB2 Recettes, dépenses et bénéfices (EUR Millions )
Date	Les revenus	Dépenses G+A	Dépenses de R&D
31 Dec 23	-17	5	9
30 Sep 23	-18	5	11
30 Jun 23	-20	5	13
31 Mar 23	-22	6	14
31 Dec 22	-24	7	16
30 Sep 22	-27	8	17
30 Jun 22	-30	9	19
31 Mar 22	-31	8	19
31 Dec 21	-31	7	20
30 Sep 21	-28	6	16
30 Jun 21	-25	5	12
31 Mar 21	-25	4	11
31 Dec 20	-26	4	10
30 Sep 20	-24	4	10
30 Jun 20	-22	4	9
31 Mar 20	-22	6	9
31 Dec 19	-19	7	9
30 Sep 19	-19	7	10
30 Jun 19	-18	8	10
31 Mar 19	-15	5	10
31 Dec 18	-14	4	10
30 Sep 18	-13	4	9
30 Jun 18	-12	3	8
31 Mar 18	-12	3	8
31 Dec 17	-11	3	7
30 Sep 17	-10	3	6
30 Jun 17	-9	3	6
31 Mar 17	-9	3	5
31 Dec 16	-8	3	5
30 Sep 16	-8	3	4
30 Jun 16	-7	3	4
31 Mar 16	-6	3	3
31 Dec 15	-5	3	2
30 Sep 15	-4	2	1
30 Jun 15	-2	1	1
31 Mar 15	-1	1	0
31 Dec 14	-1	0	0

Des revenus de qualité: 6XB2 n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: 6XB2 n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: 6XB2 n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 4.9% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de 6XB2 au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: 6XB2 n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( -18.2% ).

Rendement des fonds propres

ROE élevé: Le passif 6XB2 dépasse son actif, il est donc difficile de calculer son rendement des capitaux propres.

Biophytis Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

Recent updates

Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet

Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel

Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months

Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19

Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19

Biophytis S.A. Announces Executive Changes

Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia

Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound

Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million.

Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

Biophytis Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

Biophytis S.A. Announces Promising Top Line Results of Its Phase 2-3 Cova Clinical Study in COVID-19-Related Respiratory Failure

Biophytis SA to Update on the Development of Sarconeos (BIO101) in Covid-19 at 4th Annual Longevity Therapeutics Summit

Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia At the 15th SCWD International Congress

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease

Biophytis SA, Annual General Meeting, Jun 03, 2022

Biophytis SA Announces Chief Financial Officer Changes

Biophytis Sa Receives Approval from the ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients Through an Expanded Access Program

Biophytis SA to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Biophytis to Present Full Results from the Sara-INT Phase 2B Trial of Sarconeos in Sarcopenia At the 11Th Annual International Conference

Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 Cova Study with Sarconeos (Bio101) in Covid-19

Biophytis SA Receives Favorable Recommendation from Data Monitoring Committee Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the Cova Study in COVID-19

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

Biophytis SA to Release Topline Results for SARA-INT Phase 2 Study in August 2021

Biophytis SA Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

BIOPHYTIS Completes Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the Second Interim Analysis

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

Biophytis SA, Annual General Meeting, Apr 26, 2021

Biophytis Sa Announces That Patient Recruitment Will Begin in France and Belgium for Part 2 of Its Cova Study Assessing Sarconeos

Ventilation des recettes et des dépenses

Historique des gains et des recettes

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Rendement des fonds propres

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé